FCN-338
FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor, exhibiting an IC50 of 4.5 nM for the Bcl-2/BAK interaction. It effectively suppresses tumor growth in mouse models of follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenografts without causing significant weight loss. FCN-338 demonstrates broad-spectrum anticancer activity, making it suitable for treating FL, chronic lymphocytic leukemia (CLL) /small lymphocytic leukemia (SLL), AML, and ALL.
Product Specifications
CAS Number
2248046-39-9
Field of Research
Cell Biology
Smiles
N (=O) (=O) C1=C2C (=CC (S (NC (=O) C3=C (OC=4C=C5C (=NC4) NC=C5) C=C (C=C3) N6CCN (CC7=C (CC (C) (C) CC7) C8=CC=C (Cl) C=C8) CC6) (=O) =O) =C1) OC[C@H] (CC9=CC=CC=C9) N2
Molecular Formula
C48H48ClN7O7S
Molecular Weight
902.46
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-E596072-50MG 50 mg
Erdosteine Homocysteine Impurity Sodium Salt
Sign In for Pricing
View Details 
BNC042595-500 1x 500 µL
PAX5 / BSAP (Early B-Cell Marker) (PAX5/2595), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 